Description
| Product Name: | Anti-Human TIGIT (Tiragolumab) |
| SKU: | IVMB0551 |
| Size: | 500 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | RG6058 |
| Target: | TIGIT |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | ELISA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Muted |
| Synonyms: | VSIG9, VSTM3, WUCAM, T cell immunoreceptor with Ig and ITIM domains |
| Product Concentration: | ≥ 5.0 mg/ml |
| Purity: | ≥95% by SDS Page |
| Immunogen: | Humanized antibody that binds TIGIT |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| Antigen Distribution: | TIGIT is expressed on activated CXCR5 + CD4 + T cells in peripheral blood, variably on CD8 + T cells and CD56 + CD3 - NK cells, and constitutively in tonsils on some CD3 + CD8 int T cells as well as the CXCR5 high /ICOS high subset of CD4 + T cells that contains fully differentiated TFH cells. |
| Formulation: | This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tiragolumab.Tiragolumab activity is directed against human TIGIT. |
| Additional Applications Reported In Literature: | ELISA WB |
TIGIT (WUCAM) is an immunoreceptor that inhibits multiple immune cell responses, including T cell priming by dendritic cells, tumor cell killing by NK cells and cytotoxic T cells, and also enhances the immune suppressive activity of regulatory T cells. TIGIT is a novel member of the Ig-superfamily distantly related to Nectins and Necls that aligns with the distal Ig-V-type domains of Nectin1-4, poliovirus receptor (PVR; CD155), DNAM-1 (CD226), and TACTILE (CD96). TIGIT is preferentially expressed on human B helper follicular T cells and binds with high affinity to PVR under both static and flow conditions. Additionally, TIGIT, DNAM-1, and TACTILE are expressed together on T cells and NK cells and share PVR as a ligand. TIGIT is not detectable on the surface of resting peripheral blood mononuclear cells from healthy donors unless activated.
Tiragolumab is an investigational, fully human monoclonal antibody designed to prevent TIGIT interaction with its principal ligand CD155 (PVR; poliovirus receptor). Its immunotherapeutic effects are being evaluated as a single agent and in combination with the anti-PD-L1 antibody atezolizumab.
| Ligand/Receptor: | CD155 (PVR) & CD112 (PVRL2/NECTIN-2) |
| State of Matter: | Liquid |
| Regulatory Status: | Research Use Only |
| Product Preparation: | Recombinant biosimilar antibodies are manufactured in an animal free facility using onlyin vitroprotein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Pathogen Testing: | To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. |
| Storage and Handling: | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| UniProt: | Q495A1 |
| Research Area: | Biosimilars |
